Biophytis Management

Management criteria checks 4/4

Biophytis' CEO is Stanislas Veillet, appointed in May 2015, has a tenure of 9.5 years. total yearly compensation is €349.00K, comprised of 71.6% salary and 28.4% bonuses, including company stock and options. directly owns 0.9% of the company’s shares, worth $14.81K. The average tenure of the management team and the board of directors is 5.1 years and 5.2 years respectively.

Key information

Stanislas Veillet

Chief executive officer

€349.0k

Total compensation

CEO salary percentage	71.6%
CEO tenure	9.5yrs
CEO ownership	0.9%
Management average tenure	5.1yrs
Board average tenure	5.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Stanislas Veillet's remuneration changed compared to Biophytis's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-€15m
Mar 31 2024	n/a	n/a	-€16m
Dec 31 2023	€349k	€250k	-€17m
Sep 30 2023	n/a	n/a	-€18m
Jun 30 2023	n/a	n/a	-€20m
Mar 31 2023	n/a	n/a	-€22m
Dec 31 2022	€428k	€250k	-€24m
Sep 30 2022	n/a	n/a	-€27m
Jun 30 2022	n/a	n/a	-€30m
Mar 31 2022	n/a	n/a	-€31m
Dec 31 2021	€460k	€250k	-€31m
Sep 30 2021	n/a	n/a	-€28m
Jun 30 2021	n/a	n/a	-€25m
Mar 31 2021	n/a	n/a	-€25m
Dec 31 2020	€374k	€250k	-€26m
Sep 30 2020	n/a	n/a	-€24m
Jun 30 2020	n/a	n/a	-€22m
Mar 31 2020	n/a	n/a	-€22m
Dec 31 2019	€310k	€250k	-€19m
Sep 30 2019	n/a	n/a	-€19m
Jun 30 2019	n/a	n/a	-€18m
Mar 31 2019	n/a	n/a	-€15m
Dec 31 2018	€295k	€225k	-€14m
Sep 30 2018	n/a	n/a	-€13m
Jun 30 2018	n/a	n/a	-€12m
Mar 31 2018	n/a	n/a	-€12m
Dec 31 2017	€447k	€150k	-€11m

Compensation vs Market: Stanislas's total compensation ($USD363.43K) is below average for companies of similar size in the US market ($USD650.80K).

Compensation vs Earnings: Stanislas's compensation has been consistent with company performance over the past year.

CEO

Stanislas Veillet (59 yo)

9.5yrs

Tenure

€349,000

Compensation

Mr. Stanislas Veillet, Ph D., serves as Chairman of the Board and Chief Executive Officer of Biophytis SA since May 22, 2015. Mr. Veillet is the Co-founder of Biophytis (created in 2006) and served as its...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Stanislas Veillet	Chairman of the Board & CEO	9.5yrs	€349.00k	0.90% $ 14.8k
Waly Dioh	Chief Clinical Operating Officer	5.1yrs	no data	0.0060% $ 99.1
Pierre Dilda	Chief Scientific Officer	5.1yrs	no data	0.0032% $ 51.9
Rene Lafont	Scientific Advisor & Member of Scientific Advisory Board	5.2yrs	no data	no data
Rob van Maanen	Chief Medical Officer	3.2yrs	no data	0% $ 0
Edouard Bieth	Chief Business Officer	1.2yrs	no data	no data
Chiara Baccelli	Chief Pharmaceutical Operations Officer & Quality Assurance Director	1.8yrs	no data	0% $ 0
_ Teylan	Financial Controller	no data	no data	no data

5.1yrs

Average Tenure

54.5yo

Average Age

Experienced Management: BPTS.Y's management team is seasoned and experienced (5.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Stanislas Veillet	Chairman of the Board & CEO	9.5yrs	€349.00k	0.90% $ 14.8k
Rene Lafont	Scientific Advisor & Member of Scientific Advisory Board	5.2yrs	no data	no data
Claude Allary	Independent Director	3.3yrs	€25.00k	0% $ 0
Jose-Alain Sahel	Member of Scientific Advisory Board	no data	no data	no data
Thomas Voit	Member of Scientific Advisory Board	7.1yrs	no data	no data
Roger Fielding	Member of Scientific Advisory Board	8.5yrs	no data	no data
Jean Mariani	Chairman of Scientific Advisory Board & Director	8.6yrs	€25.00k	0% $ 0
Nadine Coulm	Independent Director	9.5yrs	€25.00k	0.000060% $ 1.0
Yann Meunier	Member of Scientific Advisory Board	less than a year	no data	no data
Bernard Levy	Member of Scientific Advisory Board	less than a year	no data	no data
Dennis Villareal	Member of Scientific Advisory Board	less than a year	no data	no data
Francisco Guarner	Member of Scientific Advisory Board	less than a year	no data	no data

5.2yrs

Average Tenure

69yo

Average Age

Experienced Board: BPTS.Y's board of directors are considered experienced (5.2 years average tenure).

Biophytis Management

Management criteria checks 4/4

Key information

Recent management updates

Biophytis S.A., Annual General Meeting, Jun 24, 2024

Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity

Biophytis S.A., Annual General Meeting, Mar 18, 2024

Biophytis S.A. Appoints Yann Meunier and Bernard L vy to its Scientific Advisory Board

Biophytis S.A. Announces Executive Changes

Biophytis S.A., Annual General Meeting, Jun 16, 2023

Recent updates

Biophytis SA Obtains IND Approval from the FDA to Start Its Phase 2 Oba Study in Obesity

Biophytis S.A., Annual General Meeting, Jun 24, 2024

Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity

Biophytis S.A.(OTCPK:BPTS.Y) dropped from NASDAQ Composite Index

Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity

Biophytis SA Launches OBA Phase 2 Clinical Study in Obesity with BIO101 (20-Hydroxyecdysone)

Biophytis S.A., Annual General Meeting, Mar 18, 2024

Biophytis S.A. Announces the Publication of the Results of its COVA Phase 2-3 Study in eClinicalMedicine, Part of The Lancet

Biophytis S.A. and the University of Li Ge Explore the Potential of Sarconeos (BIO101) in the Treatment of Viral Respiratory Diseases

Biophytis S.A. Appoints Yann Meunier and Bernard L vy to its Scientific Advisory Board

Biophytis Receives Notice of Delisting from Nasdaq and Announces It Will Request A Hearing Before the Nasdaq Hearings Panel

Biophytis S.A. Provides an Update on the Progress of its R&D Projects over the 1St Half of the Year and the Last Few Months

Biophytis SA Provides Update on its Early Access Programs for Sarconeos (BIO101) in Treatment of Severe Forms of COVID-19

Biophytis SA Receives Response from the French National Authority for Health to Request for Early Access Authorization in France for Patients Suffering from Severe Forms of COVID-19

Biophytis S.A. Announces Executive Changes

Biophytis Obtains Fda Authorization to Initiate the Sara-31 Phase 3 Study in Sarcopenia

Biophytis SA Announces Next Regulatory Steps in Europe and the United States for its COVA Project

Biophytis SA Receives Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe

Biophytis S.A. Files for a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19

Biophytis and Seqens Sign A Partnership to Produce Sarconeos (Bio101) Active Compound

Biophytis SA Filed with the FDA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia

Biophytis SA Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress

Biophytis S.A., Annual General Meeting, Jun 16, 2023

Biophytis S.A. has completed a Follow-on Equity Offering in the amount of €2.302535 million.

Biophytis SA Files for Pre-Submission Meeting Request with the European Medicine Agency (EMA) to Discuss Filing for Conditional Marketing Authorisation (CMA) in Europe

Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19

Biophytis S.A. Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd

Biophytis to Take Appropriate Measures After Receiving Nasdaq Deficiency Notice

Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19

Biophytis Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

Biophytis S.A. Announces Promising Top Line Results of Its Phase 2-3 Cova Clinical Study in COVID-19-Related Respiratory Failure

Biophytis SA to Update on the Development of Sarconeos (BIO101) in Covid-19 at 4th Annual Longevity Therapeutics Summit

Biophytis Presents the Development of Sarconeos in Phase 3 for the Treatment of Sarcopenia At the 15th SCWD International Congress

Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), A Rare Neuromuscular Disease

Biophytis SA, Annual General Meeting, Jun 03, 2022

Biophytis SA Announces Chief Financial Officer Changes

Biophytis Sa Receives Approval from the ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients Through an Expanded Access Program

Biophytis SA to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3

Biophytis to Present Full Results from the Sara-INT Phase 2B Trial of Sarconeos in Sarcopenia At the 11Th Annual International Conference

Biophytis SA Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 Cova Study with Sarconeos (Bio101) in Covid-19

Biophytis SA Receives Favorable Recommendation from Data Monitoring Committee Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the Cova Study in COVID-19

Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021

Biophytis SA to Release Topline Results for SARA-INT Phase 2 Study in August 2021

Biophytis SA Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study

BIOPHYTIS Completes Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the Second Interim Analysis

Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021

Biophytis SA, Annual General Meeting, Apr 26, 2021

Biophytis Sa Announces That Patient Recruitment Will Begin in France and Belgium for Part 2 of Its Cova Study Assessing Sarconeos

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age